Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models

European Journal of Pharmacology

Volumn 630, Issue 1-3, 2010, Pages 112-120

  McLeod, Robbie L ^a   Tulshian, Deen B ^a   Bolser, Donald C ^c   Varty, Geoffrey B ^a   Baptista, Marco ^a   Fernandez, Xiomara ^a   Parra, Leonard E ^a   Zimmer, Jennifer C ^a   Erickson, Christine H ^a   Ho, Ginny D ^a   Jia, Yanlin ^a   Ng, Fay W ^a   Korfmacher, Walter ^b   Xu, Xiaoying ^b   Veals, John ^b   Smith Torhan, April ^a   Wainhaus, Samuel ^b   Fawzi, Ahmad B ^a   Austin, Theodore M ^a   van Heek, Margaret ^a   Hey, John A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b Drug Metabolism and Pharmacokinetics   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antitussive; Cough; Nociceptin orphanin FQ; NOP receptor; SCH 486757

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 8 [BIS(2 CHLOROPHENYL)METHYL] 3 (2 PYRIMIDINYL) 8 AZABICYCLO[3.2.1]OCTAN 3 OL; ANTITUSSIVE AGENT; BACLOFEN; CAPSAICIN; CODEINE; DEXTROMETHORPHAN; HYDROCODONE; NALTREXONE; NOCICEPTIN RECEPTOR AGONIST; SCH 487675; UNCLASSIFIED DRUG;

ABDOMINAL WALL MUSCULATURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CAT; CONTROLLED STUDY; COUGHING; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ELECTROMYOGRAM; GUINEA PIG; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTITUSSIVE AGENTS; AZABICYCLO COMPOUNDS; CATS; COUGH; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; MALE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID;

EID: 77649187506     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.12.003     Document Type: Article

References (45)

1. Ackermann B. Current applications of liquid chromatography/mass spectrometry in pharmaceutical discovery after a decade of innovation. Annu. Rev. Anal. Chem. 2008, 1:357-396.
2. Bardo M.T., Rowlett J.K., Harris M.J. Conditioned place preference using opiate and stimulant drugs: a meta-analysis. Neurosci. Biobehav. Rev. 1995, 19:39-51.
3. Bigoni R., Calo G., Rizzi A., Guerrini R., De Risi C., Hashimoto Y., Hashiba E., Lambert D.G., Regoli D. In vitro characterization of J113397, a non-peptide nociceptin/orphanin FQ receptor antagonist. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 361:565-568.
4. Bolser D.C., Davenport P.W. Codeine and cough: an ineffective gold standard. Curr. Opin. Allergy Clin. Immunol. 2007, 7:32-36.
5. B agonist in the cat and guinea pig. Br. J. Pharmacol. 1993, 110:491-495.
6. Bolser D.C., McLeod R.L., Tulshian D.B., Hey J.A. Antitussive action of nociceptin in the cat. Eur. J. Pharmacol. 2001, 430:107-111.
7. Bunzow J.R., Saez C., Mortrud M., Bouvier C., Williams J.T., Low M., Grandy D.K. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett. 1994, 347:284-288.
8. Calo G., Guerrini R., Rizzi A., Salvadori S., Regoli D. Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br. J. Pharmacol. 2000, 129:1261-1283.
9. Canning B.J. Encoding of the cough reflex. Pulm. Pharmacol. Ther. 2007, 20:396-401.
10. Cherry D.K., Woodwell D.A. National Ambulatory Medical Care Survey 2000 Summary. Advance data from vital and health statistics 2002, vol. 328:1-32.
11. Choudry N.B., Fuller R.W. Sensitivity of the cough reflex in patients with chronic cough. Eur. Respir. J. 1992, 5:296-300.
12. Ciccocioppo R., Economidou D., Fedeli A., Massi M. The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats. Physiol. Behav. 2003, 79:121-128.
13. Ciccocioppo R., Economidou D., Fedeli A., Angeletti S., Weiss F., Helig M., Massi M. Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behavior by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology 2004, 172:170-178.
14. Corboz M.R., Rivelli M.A., Egan R.W., Tulshian D., Matasi J., Fawzi A.B., Benbow L., Smith-Torhan A., Zhang H., Hey J.A. Nociceptin inhibits capsaicin-induced bronchoconstriction in isolated guinea pig lung. Eur. J. Pharmacol. 2000, 18:171-179.
15. 1 receptor. Nature 1995, 377:532-535.
16. Fawzi A.B., Zhang H., Weig B., Hawes B., Graziano M. N/OFQ activation of the human ORL1 receptor expresses in Chinese hamster ovary cells: functional homology with opioid receptors. Eur. J. Pharmacol. 1997, 336:233-242.
17. Fisher A., Forssman W.G., Undem B.J. N/OFQ-induced inhibition of tachykinergic neurotransmission in guinea pig bronchus. J. Pharmacol. Exp. 1998, 268:85-89.
18. Giuliani S., Lecci A., Maggi C.A. N/OFQ and neurotransmitter release in the periphery. Peptides 2000, 21:977-984.
19. Ho G.D., Anthes J., Bercovici A., Caldwell J.P., Cheng K.C., Cui X., Fawzi A., Fernandez X., Greenlee W.J., Hey J.A., Korfmacher W., Lu S.X., McLeod R.L., Ng F., Smith-Torhan A., Tan Z., Tulshian D., Varty G.B., Xu L., Zhang H. The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett 2009, 19:2519-2523.
20. Hsieh Y. HPLC-MS/MS in drug metabolism and pharmacokinetic screening. Expert Opin. Drug. Metab. Toxicol. 2008, 4:93-101.
21. Irwin R.S., Richter J.E. Gastroesophageal reflux and cough. Am. J. Gastroenterol. 2000, 95:S9-S14.
22. Jia Y., Wang X., Aponte S.I., Rivelli M.A., Yang R., Rizzo C., Corboz M.R., Priestley T., Hey J.A. Nociceptin inhibits capsaicin-induced guinea pig airway contraction through an inward-rectifier potassium channel. Br. J. Pharmacol. 2002, 135:764-770.
23. Kapusta D.R. Neurohumoral effects of orphanin FQ/N/OFQ: relevance to cardiovascular and renal function. Peptides 2000, 21:1081-1099.
24. Korfmacher W.A. Principles and applications of LC-MS in new drug discovery. Drug Discov. Today 2005, 10:1357-1367.
25. Korfmacher W.A., Cox K.A., Bryant M.S., Veals J., Ng K., Watkins R., Lin C.-C. HPLC-API/MS/MS: a powerful tool for integrating drug metabolism into the drug discovery process. Drug. Discov. Today 1997, 2:532-537.
26. Kuehn B.M. Citing serious risks, FDA recommends no cold and cough medicines for infants. JAMA 2008, 299:887-888.
27. Lee M.G., Undem B.J., Brown C., Carr M.J. Effect of nociceptin in acid-evoked cough and airway sensory nerve activation in guinea pigs. Am. J. Respir. Crit. Care Med. 2006, 173:271-275.
28. Lindgren B.R., Andersson R.G. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review. Med. Toxicol. Adverse Drug Exp. 1989, 4:369-380.
29. McLeod R.L., Mingo G., O'Reilly S., Ruck L.A., Bolser D.C., Hey J.A. Antitussive action of antihistamines is independent of sedative and ventilation activity in the guinea pig. Pharmacology 1998, 57:57-64.
30. McLeod R.L., Parra L.E., Mutter J.C., Erickson C.H., Carey G.J., Tulshian D.B., Fawzi A.B., Smith-Torhan A., Egan R.W., Cuss F.M., Hey J.A. Nociceptin inhibits cough in the guinea-pig by activation of ORL(1) receptors. Br. J. Pharmacol. 2001, 132:1175-1178.
31. McLeod R.L., Bolser D.C., Jia Y., Parra L.E., Mutter J.C., Tulshian D.B., Egan R.W., Hey J.A. Antitussive effect of nociceptin/orphanin FQ in experimental cough models. Pulm. Pharmacol. Ther. 2002, 15:213-216.
32. McLeod R.L., Tulshian D.B., Hey J.A. Novel pharmacological targets and potential progression of new antitussive drugs. Expert Opin Ther Patents 2003, 13:1501-1512.
33. McLeod R.L., Jia Y., Fernandez X., Parra L.E., Wang X., Tulshian D.B., Fawzi A.B., Smith-Torhan A., Hey J.A. Antitussive profile of the NOP agonist Ro64-6198 in the guinea pig. Pharmacology 2004, 71:143-149.
34. McLeod R.L., Tulshian D.B., Ho G.D., Fernandez X., Bolser D.C., Parra L.E., Zimmer J.C., Erickson C.H., Fawzi A.B., Jyappa H., Lehr C., Erskine J., Smith-Torhan A., Zhang H., Hey J.A. A novel NOP receptor agonist (SCH 225288) attenuates guinea pig irritant-evoked, feline mechanically-induced and canine infectious tracheobronchitis cough. Pharmacology. 2009, 84:153-161.
35. 1 receptor. Nature 1995, 377:532-535.
36. 1, a novel member of the opioid receptor family-cloning, functional expression and localization. FEBS Lett. 1994, 341:33-38.
37. Morice A.H. Epidemiology of chronic cough. Eur. Respir. Rev. 2002, 85:222-225.
38. Novitsky Y.W., Zawachi J.K., Irwin R.S., French C.T., Hussey V.M., Callery M.P. Chronic cough due to gastroesophageal reflux disease: efficacy of antireflux surgery. Surg. Endoscop. 2002, 16:567-571.
39. 1 receptor antagonist. Eur. J. Pharmacol. 2000, 402:45-53.
40. Reinscheid R.K., Ardati A., Monsma F.J., Civelli O. Structure-activity relationship studies on the novel neuropeptide orphanin FQ. J. Biol. Chem. 1996, 271:14163-14168.
41. Rimsza M.E., Newberry S. Unexpected infant deaths associated with use of cough and cold medications. Pediatrics 2008, 122:e318-e322.
42. Schaefer M.K., Shehab N., Cohen A.L., Budnitz D.S. Adverse events from cough and cold medications in children. Pediatrics 2008, 121:783-787.
43. Spyraki C., Fibiger H.C., Phillips A.G. Cocaine-induced place preference conditioning: lack of effects of neuroleptics and 6-hydroxydopamine lesions. Brain Res. 1982, 253:195-203.
44. Yang S.-W., Ho G., Tulshian D.B., Greenlee W.J., Tan Z., Zhang H., Fawzi A., Anthes J., Varty G., Fernandez X., McLeod R.L., Hey J.A. Identification of 3-substituted N-benzhydrl-nortropane analogs as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett 2009, 19:2482-2486.
45. Zhao R.J., Woo R.S., Jeong M.S., Shin B.S., Kim D.G., Kim K.W. Orphanin FQ/nociceptin blocks methamphetamine place preference in rats. Neuroreport 2003, 14:2383-2385.